Directors

Tom Bannatyne - Chairman

Tom Bannatyne, 47, has well over 20 years' experience of the investment industry. After graduating from Queens' College, Cambridge with an M.A. in Chemical Engineering, he spent 9 years with the S.G. Warburg Group (since acquired by UBS), in London and Geneva, and was a Director of European Equities. In 1994 he joined the Tudor Group, a privately-owned major international hedge fund, establishing and managing its European Equities business. At Tudor he was a partner, member of the Management Committee, and Chairman of the group's UK operation, as well as of the UK branch of the group's charitable foundation. Since retiring from Tudor at the end of 2007, he has been pursuing his own investment interests. Tom was appointed to the Board of Syntopix in February 2010.

Dr Stephen P. Jones - Chief Executive Officer

Stephen is a highly experienced pharmaceutical industry executive with a track record in both branded medicines and consumer healthcare and a successful history of new product development. At Syntopix, he co-ordinates operational activities and commercial relationships. Stephen was most recently at GlaxoSmithKline (GSK) where he held the position of Vice President and Director of Consumer Healthcare Research and Development. Prior to joining GSK Stephen worked for companies including Scherer Drug Delivery Systems, Sterling Winthrop, Beecham Pharmaceutical's Research Division, Merck Sharp & Dohme and Amersham International.

Dr Anne Eady - Scientific Director

Anne is a founder shareholder of Syntopix and is an internationally recognised skin microbiologist, with particular expertise in acne, acne clinical trial methodology and the dermatological use of antibiotics. She has worked extensively with clinicians and pharmaceutical companies on a variety of basic and applied research projects and has advised on microbiological aspects of a number of regulatory submissions. Anne is an Honorary Research Fellow in Dermatology at Harrogate District Hospital.

Dr Jon Cove - Research Director

Jon is a founder shareholder of Syntopix and is currently seconded to the Group from the University of Leeds, where he is a senior lecturer at the Institute of Molecular and Cellular Biology. Jon's areas of expertise are in the evolution and mechanisms of antibiotic resistance in skin bacteria and he has previous experience of working in the pharmaceutical industry. In collaboration with Anne Eady, Jon has established research and/or consultancy with commercial sponsors, including Galderma, Roche, Sanofi-Aventis, Unilever, Stiefel, Smith and Nephew and ProStrakan.

Darren Bamforth - Finance Director

Darren is a Chartered Accountant and a Director of Atraxa Consulting Limited, his own business advisory practice which specialises in supporting early stage and growing companies. Darren has been the Finance Director of the Group, on a consultancy basis, since the formation of Syntopix. Prior to establishing his own practice in 2002, Darren was a Senior Manager with KPMG.

Dr Gwyn Humphreys - Senior Non-executive Director

Gwyn was a founder and Managing Director of Bradford Particle Design Limited, a successful UK university spin-out company, which developed supercritical fluid technology used to control particle size in drug formulation. Bradford Particle Design Limited was sold in January 2001 to Inhale Therapeutics Inc. (since re-named Nektar Therapeutics Inc.) for $200 million. Gwyn became a shareholder of Syntopix and was then appointed Chairman of Syntopix in October 2004. Gwyn is a member of the Nomination Committee, Remuneration Committee and Audit Committee.

Mike Townend - Non-executive Director

Mike has 17 years experience in all aspects of equity capital markets and joined IP Group from Lehman Brothers where he was Managing Director, European Equities and Head of Equity Sales to Hedge Funds. Prior to this, Mike was an Executive Director at Donaldson, Lufkin and Jenrette where he was recruited to build up business with hedge funds. He also has a further eight years equity sales experience at Banque Paribas and BG Bank where he was Head of Equity Sales. Mike is also non-executive director of Modern Water, Revolymer Limited and GUT. Mike lives in South West London with his wife Karenza and 10 year old son Theo. Mike is a member of the Nomination Committee, Remuneration Committee and Audit Committee.

Employees

The Group also employs nine scientists and support staff who work at the Group's registered office.

Syntopix

share price

64.00p